MaxCyte (MXCT) (GB:MXCT) has released an update.
MaxCyte Inc. has expanded its stock capital with an issuance of 148,715 new shares following the exercise of share options and vesting of restricted stock units, bringing the total issued stock capital to 104,544,289 shares as of April 30, 2024. This figure is crucial for shareholders to determine their notification requirements regarding any change in their interest in the company’s stock capital. MaxCyte, renowned for its cell engineering platforms used in cell-based therapeutics and bioprocessing applications, continues to support the cell therapy market with its proprietary ExPERT platform and related products.
For further insights into GB:MXCT stock, check out TipRanks’ Stock Analysis page.
